All In Biotech

Drug Trial Radar · NCT03491683

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

52

Actual

Start

May 31, 2018

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Inovio PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).

Conditions

  • Glioblastoma

Interventions

  • INO-5401Biological

    INO-5401 is a combination of 3 separate DNA plasmids targeting Wilms tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) genes. Starting on Day 0 three milligrams (mg) of each plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by immunotherapy Response Assessment in Neuro-Oncology (iRANO), unacceptable toxicity, withdrawal of consent, or death.

  • INO-9012Biological

    INO-9012 is a DNA plasmid for expression of human interleukin-12 (IL-12). Starting on Day 0 one mg plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.

  • CemiplimabBiological

    Cemiplimab is an antibody to programmed death-1 (PD-1) protein. Starting on Day 0 cemiplimab will be administered intravenously (IV) every three weeks at a dose of 350 mg per dose in the absence of dose holding, until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.

  • Radiation TherapyRadiation

    Radiation therapy (RT) will begin no later than 42 days after surgical intervention, and should start approximately 2 weeks after Day 0. RT will be given for three weeks.

  • TemozolomideDrug

    Temozolomide (TMZ) will be given daily during radiation therapy (RT) at a dose of 75 milligrams per square meter (mg/m\^2).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Adverse Events (AEs)Time frame: From Day 0 to 30 days after the last dose of study treatment (non-serious AEs) and to 6 months after the last dose of study treatment (immune-related AEs, AEs of special interest and serious AEs) up to approximately 24 months

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • Stanford University, School of Medicine

    Palo Alto, California

  • University of California, San Francisco

    San Francisco, California

  • University of Miami - Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • Rutgers University - Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • New York University Langone Medical Center; Perlmutter Cancer Center

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Columbia University Medical Center The Neurological Institute of New York

    New York, New York

  • New York-Presbyterian Hospital/Weill Cornell Medical Center

    New York, New York

  • University of North Carolina School of Medicine

    Chapel Hill, North Carolina

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Oregon Health & Science University

    Portland, Oregon

  • University of Pennsylvania Health System: Penn Medicine

    Philadelphia, Pennsylvania

  • UPMC Cancer Center Neuro-Oncology; UPMC Cancer Pavilion

    Pittsburgh, Pennsylvania

  • Texas Oncology

    Austin, Texas

  • Baylor College of Medicine

    Houston, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.